Indaptus Therapeutics, Inc. Accounts Payable, Other, Current
Indaptus Therapeutics, Inc. (INDP) had Accounts Payable, Other, Current of $273.00 thousand as of 2021-06-30, per its 10-Q filed 2021-08-16.
Discontinued › Notes › Accounts Payable and Accrued Liabilities, Current › Accounts Payable, Current
us-gaap:AccountsPayableOtherCurrent · last filed 2021-08-16
- 2021-06-30: Accounts Payable, Other, Current $273.00K.
- 2020-12-31: Accounts Payable, Other, Current $274.00K.
| Period end | Accounts Payable, Other, Current |
|---|---|
| 2021-06-30 | $273.00K 10-Q · filed 2021-08-16 |
| 2020-12-31 | $274.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |